Written by
Bilal H
Bilal H Liv Hospital Content Team
Medically reviewed by

Related Doctors

Assoc. Prof. MD. Evrim Duman Liv Hospital Ulus Assoc. Prof. MD. Evrim Duman Radiation Oncology Asst. Prof. MD. Meltem Topalgökçeli Selam Liv Hospital Ulus Asst. Prof. MD. Meltem Topalgökçeli Selam Medical Oncology Prof. MD. Duygu Derin Liv Hospital Ulus Prof. MD. Duygu Derin Medical Oncology Prof. MD. Emre Merdan Fayda Liv Hospital Ulus Prof. MD. Emre Merdan Fayda Radiation Oncology Prof. MD. Meral Günaldı Liv Hospital Ulus Prof. MD. Meral Günaldı Medical Oncology Assoc. Prof. MD. Murat Ayhan Liv Hospital Vadistanbul Assoc. Prof. MD. Murat Ayhan Medical Oncology Prof. MD.  Itır Şirinoğlu Demiriz Liv Hospital Vadistanbul Prof. MD. Itır Şirinoğlu Demiriz Hematology Prof. MD. Tülin Tıraje Celkan Liv Hospital Vadistanbul Prof. MD. Tülin Tıraje Celkan Pediatric Hematology and Oncology Assoc. Prof. MD. Erkan Kayıkçıoğlu Liv Hospital Bahçeşehir Assoc. Prof. MD. Erkan Kayıkçıoğlu Medical Oncology Assoc. Prof. MD. Mine Dağgez Liv Hospital Bahçeşehir Assoc. Prof. MD. Mine Dağgez Gynecological Oncology Assoc. Prof. MD. Ozan Balakan Liv Hospital Bahçeşehir Assoc. Prof. MD. Ozan Balakan Medical Oncology MD. Taylan Bükülmez Liv Hospital Bahçeşehir MD. Taylan Bükülmez Radiation Oncology Op. MD. Alp Koray Kinter Liv Hospital Bahçeşehir Op. MD. Alp Koray Kinter Gynecological Oncology Prof. MD. Nuri Faruk Aykan Liv Hospital Bahçeşehir Prof. MD. Nuri Faruk Aykan Medical Oncology Prof. MD. Yasemin Altuner Torun Liv Hospital Bahçeşehir Prof. MD. Yasemin Altuner Torun Pediatric Hematology and Oncology Spec. MD. Özlem Doğan Liv Hospital Bahçeşehir Spec. MD. Özlem Doğan Medical Oncology Assoc. Prof. MD. Emir Çelik Liv Hospital Topkapı Assoc. Prof. MD. Emir Çelik Medical Oncology Assoc. Prof. MD. Muhammed Mustafa Atcı Liv Hospital Topkapı Assoc. Prof. MD. Muhammed Mustafa Atcı Medical Oncology Prof. MD. İrfan Çiçin Liv Hospital Topkapı Prof. MD. İrfan Çiçin Medical Oncology Assoc. Prof. MD.  Ramazan Öcal Liv Hospital Ankara Assoc. Prof. MD. Ramazan Öcal Hematology Assoc. Prof. MD. Nazlı Topfedaisi Özkan Liv Hospital Ankara Assoc. Prof. MD. Nazlı Topfedaisi Özkan Gynecological Oncology Prof. MD. Fikret Arpacı Liv Hospital Ankara Prof. MD. Fikret Arpacı Medical Oncology Prof. MD. Gökhan Erdem Liv Hospital Ankara Prof. MD. Gökhan Erdem Medical Oncology Prof. MD. Meral Beksaç Liv Hospital Ankara Prof. MD. Meral Beksaç Hematology Prof. MD. Oral Nevruz Liv Hospital Ankara Prof. MD. Oral Nevruz Hematology Prof. MD. Saadettin Kılıçkap Liv Hospital Ankara Prof. MD. Saadettin Kılıçkap Medical Oncology Prof. MD. Sadık Muallaoğlu Liv Hospital Ankara Prof. MD. Sadık Muallaoğlu Medical Oncology Spec. MD. Ender Kalacı Liv Hospital Ankara Spec. MD. Ender Kalacı Medical Oncology Assoc. Prof. MD. Fadime Ersoy Dursun Liv Hospital Gaziantep Assoc. Prof. MD. Fadime Ersoy Dursun Hematology Prof. MD. Fatih Teker Liv Hospital Gaziantep Prof. MD. Fatih Teker Medical Oncology Spec. MD. ELXAN MEMMEDOV Liv Bona Dea Hospital Bakü Spec. MD. ELXAN MEMMEDOV Medical Oncology Spec. MD. Ceyda Aslan Spec. MD. Ceyda Aslan Hematology Spec. MD. Elkhan Mammadov Spec. MD. Elkhan Mammadov Medical Oncology Spec. MD. Elmir İsrafilov Spec. MD. Elmir İsrafilov Hematology Spec. MD. Minure Abışova Eliyeva Spec. MD. Minure Abışova Eliyeva Hematology Spec. MD. Natavan Azizova Spec. MD. Natavan Azizova Medical Oncology Prof. MD. Mehmet Hilmi Doğu Liv Hospital Ulus + Liv Hospital Bahçeşehir Prof. MD. Mehmet Hilmi Doğu Hematology
...
Views
Read Time
...
views
Read Time
car t for lymphoma LIV Hospital
What Is CAR T Cell Therapy for Lymphoma and How Does It Work? 2

At Liv Hospital, we lead in innovative cancer treatments. CAR T cell therapy is a groundbreaking immunotherapy for lymphoma. It has shown great promise.

CAR T cell therapy changes a person’s T cells to fight cancer. It makes T cells recognize and attack cancer cells. This therapy gives hope to those with relapsed or refractory lymphoma.

We focus on giving our international patients the best care. Your health and trust are our top priorities. We aim to deliver world-class healthcare with international standards.

Key Takeaways

  • CAR T cell therapy is a revolutionary treatment for certain types of lymphoma.
  • It involves genetically modifying a patient’s T cells to recognize and attack cancer cells.
  • Liv Hospital is committed to providing innovative cancer treatments with international standards.
  • Our expertise in CAR T cell therapy offers new hope for patients with relapsed or refractory lymphoma.
  • We provide complete care and support to our international patients.

The Revolutionary Approach to Lymphoma Treatment

 CAR T cell therapy for lymphoma
What Is CAR T Cell Therapy for Lymphoma and How Does It Work? 3

Traditional treatments for lymphoma have their limits. This has led to the development of new therapies like CAR T cell therapy. For a long time, patients with lymphoma have turned to chemotherapy, radiation, and stem cell transplants. These methods work for some but can have harsh side effects and may not work for everyone, mainly those with relapsed or refractory lymphoma.

The Limitations of Traditional Lymphoma Therapies

Traditional treatments have big drawbacks. Chemotherapy can harm both cancer cells and healthy cells. Radiation therapy can damage healthy tissues around the tumor. Some patients don’t respond to these treatments or relapse after initial success. This has led to a search for more targeted and effective treatments.

Stem cell transplantation is another common treatment. It involves replacing a patient’s stem cells after high-dose chemotherapy or radiation. While effective for some, it’s not for everyone due to age, health, and donor availability. The process also carries risks like graft-versus-host disease and infections.

How CAR T Therapy Changed the Treatment Landscape

CAR T cell therapy has changed the game for lymphoma patients, mainly those with relapsed or refractory disease. It uses a patient’s own immune cells to target and destroy cancer cells. This approach minimizes harm to healthy tissues.

This therapy has brought new hope to patients who’ve tried other treatments without success. Clinical trials have shown promising results, with some patients achieving complete remission. CAR T cell therapy is a major leap forward in lymphoma treatment options, giving a second chance to those with few options before.

As CAR T cell therapy evolves, it’s becoming safer and more effective. Researchers are working to use it for more types of lymphoma and to improve patient outcomes. They aim to address side effects and enhance the therapy’s benefits.

What Is CAR T Cell Therapy?

CAR T cell therapy
What Is CAR T Cell Therapy for Lymphoma and How Does It Work? 4

CAR T Cell Therapy is a new way to fight cancer. It changes T cells to find and kill cancer cells. This treatment is helping people with lymphoma who didn’t get better with other treatments.

Defining Chimeric Antigen Receptor T Cell Therapy

Chimeric Antigen Receptor (CAR) T Cell Therapy changes T cells to fight cancer. It makes T cells better at finding and killing cancer cells. First, T cells are taken from the blood. Then, they are changed genetically and put back into the body.

The genetic change lets CAR T cells find and stick to cancer cells. This leads to the cancer cells being destroyed.

CAR T as a “Living Drug” Concept

CAR T Cell Therapy is called a “living drug” because it keeps working in the body. It’s different from other treatments because it can keep fighting cancer over time.

This means CAR T cells can protect against cancer coming back. But, it also means there can be side effects. These need to be managed carefully.

The Science Behind CAR T Cells

CAR T cells are a new way to fight cancer. They work by changing T cells, which are key to our immune system. T cells help protect us from infections and diseases.

Understanding T Cells in the Immune System

T cells are white blood cells that help fight off bad cells. They come in different types, like cytotoxic T cells. These cells can kill infected cells or start an immune response.

To make CAR T cell therapy, T cells are first taken from a patient’s blood. Then, these T cells are changed to find and attack cancer cells.

How T Cells Are Engineered to Express CARs

Changing T cells to have CARs is a detailed process. First, the T cells are made active and grown in number. Next, a gene for the CAR is added to them using viruses.

After the T cells have CARs, they are grown more and ready to be given back to the patient. The CAR helps these T cells find and kill cancer cells better.

The Role of CD19 in Targeting B-Cell Lymphomas

CD19 is a protein on B cells, making it a good target for CAR T cell therapy. This therapy can find and kill cancerous B cells.

Because CAR T cells can find CD19, they are very good at treating B-cell lymphomas. They have helped many patients who didn’t respond to other treatments.

Let’s look at how well CAR T cell therapy works against CD19-positive lymphoma cells in clinical trials.

Lymphoma TypeResponse RateComplete Response Rate
Diffuse Large B-Cell Lymphoma (DLBCL)60-80%40-60%
Relapsed/Refractory Follicular Lymphoma70-90%50-70%
Mantle Cell Lymphoma80-90%60-80%

These results show CAR T cell therapy is very effective against B-cell lymphomas.

CAR T for Lymphoma: Types and Applications

CAR T cell therapy is a new hope for lymphoma patients. It’s a groundbreaking treatment for some non-Hodgkin lymphoma types. It offers a chance for those who have tried other treatments without success.

Non-Hodgkin Lymphoma Subtypes Eligible for Treatment

CAR T cell therapy is approved for certain non-Hodgkin lymphoma types. These include diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma. It has shown great promise in treating these aggressive lymphomas.

Specific subtypes that can get CAR T cell therapy are:

  • Diffuse large B-cell lymphoma (DLBCL)
  • Primary mediastinal large B-cell lymphoma
  • High-grade B-cell lymphoma
  • Follicular lymphoma
  • Mantle cell lymphoma

When CAR T Is Recommended in the Treatment Journey

CAR T cell therapy is for patients who haven’t responded well to other treatments. It’s considered when patients have tried many treatments without lasting results. The choice to use CAR T cell therapy depends on the patient’s health, disease, and past treatments.

Key factors influencing the recommendation for CAR T cell therapy include:

  1. The number of prior therapies
  2. Response to previous treatments
  3. Disease aggressiveness
  4. Patient’s overall health status

We look at these factors to decide when to use CAR T cell therapy. This helps ensure the best chance for a positive outcome.

The Complete CAR T Cell Therapy Process

If you’re thinking about CAR T cell therapy for lymphoma, knowing the process is key. We’ll walk you through each step, from the first check-up to getting ready for treatment.

Initial Evaluation and Preparation

The first step is an initial evaluation to see if CAR T cell therapy is right for you. We look at your medical history, current health, and past treatments. We also check the type of lymphoma you have to make sure CAR T cell therapy is a good fit. Immunotherapy, including CAR T cell therapy, is considered for those who haven’t responded to other treatments or have relapsed.

T Cell Collection Through Leukapheresis

After checking if you’re a good candidate, we do leukapheresis. This is when we collect your T cells from your blood. We use a special machine to separate the T cells from other blood parts. Then, we send the T cells to a lab for more work.

Laboratory Engineering of CAR T Cells

In the lab, we genetically engineer your T cells to fight your lymphoma. We add a CAR gene to the T cells using a virus. This makes the CAR T cells grow in number and get ready for you to receive them.

Lymphodepletion Chemotherapy

Before getting the CAR T cells, you’ll have lymphodepletion chemotherapy. This clears out your lymphocytes to make room for the CAR T cells. The type of chemotherapy you get depends on your health and the CAR T cell product.

Here’s a quick summary of the CAR T cell therapy process:

StepDescription
Initial EvaluationComprehensive assessment to determine eligibility for CAR T cell therapy
LeukapheresisCollection of T cells from the patient’s blood
Laboratory EngineeringGenetic modification of T cells to express CAR
Lymphodepletion ChemotherapyChemotherapy to deplete existing lymphocytes before CAR T cell infusion
CAR T Cell InfusionInfusion of engineered CAR T cells back into the patient

CAR T Cell Therapy Success Rates for Lymphoma

CAR T cell therapy is a new hope for lymphoma patients. It’s a groundbreaking treatment for those with relapsed or refractory disease. We need to look at how well it works for different lymphoma types and what affects its success.

Response Rates Across Different Lymphoma Types

CAR T cell therapy is promising for many lymphoma subtypes. It’s most hopeful for aggressive or treatment-resistant types. The success rates depend on the lymphoma type, patient, and other factors.

In diffuse large B-cell lymphoma (DLBCL), a common non-Hodgkin lymphoma, CAR T cell therapy works well. It has overall response rates from 50% to 80%. Some studies show complete response rates up to 40%.

Lymphoma TypeOverall Response RateComplete Response Rate
DLBCL50-80%up to 40%
FL60-90%up to 50%
MCL70-90%up to 60%

Factors Affecting Treatment Success

Many things can affect how well CAR T cell therapy works. These include the lymphoma type and stage, patient age and health, past treatments, and biomarkers.

Key factors affecting treatment success:

  • Prior treatment history and response
  • Lymphoma subtype and genetic characteristics
  • Patient’s overall health and performance status
  • CAR T cell product characteristics
  • Use of lymphodepletion chemotherapy

Knowing these factors helps doctors choose the best treatment for each patient. It also helps manage what patients can expect from the treatment.

CAR T Cell Therapy Side Effects and Management

CAR T cell therapy has changed how we treat lymphoma. But, it also has side effects that we need to handle. It’s important to know about these challenges as we explore this new treatment.

Understanding Cytokine Release Syndrome

Cytokine Release Syndrome (CRS) is a big side effect of CAR T cell therapy. It happens when the CAR T cells release a lot of cytokines into the blood. This can cause symptoms from mild to severe.

Symptoms of CRS include fever, nausea, headache, and fatigue. In the worst cases, it can harm organs.

We treat CRS with medicines and supportive care. Tocilizumab, an anti-IL-6 receptor antibody, is often used. Corticosteroids may be given in severe cases.

Neurological Toxicities and ICANS

Neurological toxicity, or ICANS, is another side effect. It can cause confusion, trouble speaking, and even seizures or swelling in the brain. It’s important to catch and treat ICANS early to avoid lasting brain damage.

We watch patients closely for signs of neurological problems. We use supportive care and sometimes corticosteroids to manage it.

Strategies for Side Effect Management

Handling CAR T cell therapy side effects needs a team effort. Here are some key steps:

  • Watch patients closely for early signs of CRS and ICANS
  • Use tocilizumab and corticosteroids to manage CRS and ICANS
  • Offer supportive care, like staying hydrated, eating well, and resting

By knowing about CAR T cell therapy side effects and using good management strategies, we can reduce risks. This way, we can make the most of this new treatment.

The Patient Experience During CAR T Treatment

As CAR T cell therapy changes how we treat lymphoma, it’s key to know what patients go through. Those getting this new treatment need careful watching and support during their treatment.

Hospital Stay Requirements and Monitoring

Patients getting CAR T cell therapy often stay in the hospital for a while after the treatment. This stay is important for handling side effects like cytokine release syndrome (CRS) and brain problems.

The hospital stay helps healthcare providers to:

  • Watch for signs of CRS and other bad effects
  • Act quickly to fix side effects
  • Give support, like fluids and medicines, when needed

What Patients Can Expect During Recovery

Recovering from CAR T cell therapy takes time. Patients will go through physical and emotional changes. Key parts of recovery include:

  1. Physical Recovery: Patients might feel very tired and weak. It’s important to rest and slowly start doing more.
  2. Immune System Recovery: It takes time for the immune system to get back to normal. Patients might get sick easier.
  3. Emotional Support: The emotional side of CAR T cell therapy is big. Patients might find help from counseling or support groups.

Knowing what to expect during treatment and recovery helps patients get ready for the CAR T cell therapy journey.

CAR T Cell Therapy Cost and Access Considerations

Understanding the financial side of CAR T cell therapy is key for those thinking about it for lymphoma. The therapy’s cost is high, and dealing with the money side is a big part of the journey.

The Price of CAR T Treatment

CAR T cell therapy is one of the priciest cancer treatments, costing between $373,000 and $525,000 or more per patient. This price includes the CAR T cell product and other medical costs like hospital stays and doctor fees.

The high cost comes from the complex process of making CAR T cells. This involves taking a patient’s T cells, changing them genetically, and putting them back in. This personalized method is effective but expensive.

Insurance Coverage and Financial Assistance Programs

Many insurance plans cover CAR T cell therapy, seeing its value in treating lymphoma. But, how much coverage varies by plan.

For those struggling financially, help is available. There are:

  • Patient assistance programs from drug companies
  • Non-profit groups that help with cancer treatment costs
  • Government programs for certain patients

Patients should talk to their healthcare team and financial advisors. This helps them understand their insurance and find financial aid. This way, they can focus on getting better without worrying about money.

Regulatory Framework and Availability

It’s important for patients and doctors to know about CAR T cell therapy rules. The rules on these therapies come from government agencies around the world.

FDA-Approved CAR T Products for Lymphoma

In the U.S., the FDA has okayed CAR T cell treatments for some lymphomas. Axicabtagene ciloleucel (Yescarta) and tisagenlecleucel (Kymriah) have shown promise in studies. The FDA checks these therapies carefully to make sure they’re safe and work well.

To learn more about CAR T cell therapy rules, check out the Food and Drug Law Institute. They offer insights into CAR T cell therapy’s past, present, and future.

International Availability and Regulations

Outside the U.S., CAR T cell therapy rules and availability differ a lot. In Europe, axicabtagene ciloleucel and tisagenlecleucel are approved for some uses. But in other places, these treatments might not be available yet or are only in clinical trials.

Rules in different countries can change how people get, pay for, and use CAR T cell therapies. It’s key for patients and doctors to understand these rules to find their way through the complex world of CAR T cell therapy.

Innovations and Future Directions in CAR T Therapy

CAR T cell therapy is getting better and safer for lymphoma patients. New research is creating next-generation CAR T cells. These cells aim to fix old problems and make treatments better.

Next-Generation CAR T Cell Designs

New CAR T cell designs are being made. They aim to work better, be safer, and last longer. Some cool ideas include:

  • Armored CAR T cells that secrete cytokines to enhance anti-tumor activity
  • CAR T cells with improved trafficking to tumor sites
  • Dual-targeting CAR T cells to reduce antigen escape

These new designs are key to solving old problems with CAR T cell therapy.

Addressing Treatment Resistance Mechanisms

One big challenge is when CAR T cells stop working. Scientists are working on ways to fix this. They’re looking at:

StrategyDescription
Combination TherapiesUsing CAR T cell therapy with other treatments to make it work better
CAR T Cell EngineeringChanging CAR T cells to help them find and attack cancer cells better
Tumor Microenvironment ModulationChanging the area around tumors to make CAR T cells work better

These plans hope to make CAR T cell therapy last longer and work for more people.

Expanding CAR T Applications in Lymphoma

We’re excited about the future of CAR T cell therapy. It could change how we treat lymphoma for the better.

Conclusion: The Evolving Role of CAR T Cell Therapy in Lymphoma Care

CAR T cell therapy has changed how we treat some lymphomas. It gives hope to patients with hard-to-treat diseases. This method makes a patient’s T cells attack cancer cells, making treatment more effective and personal.

Because CAR T cell therapy works well, scientists are studying it more. They want to make it even better. They’re looking into new ways to use it and combining it with other treatments. This could make it work even better for more people.

As CAR T cell therapy gets better, it will be a big part of fighting lymphoma. It will give patients more effective and targeted treatments. By keeping up with these advances, doctors and patients can work together. They can find the best ways to treat lymphoma and help patients get better.

What is CAR T cell therapy?

CAR T cell therapy is a new treatment that changes a patient’s T cells to fight cancer. It gives hope to those with lymphoma that has come back or not responded to other treatments.

How does CAR T cell therapy work?

This therapy makes T cells find and attack cancer cells. It does this by adding special receptors to the T cells. This makes it a precise and possibly life-saving treatment.

What types of lymphoma can be treated with CAR T cell therapy?

It can treat some types of non-Hodgkin lymphoma. This includes cases that have not gotten better with other treatments.

What is the process of CAR T cell therapy?

First, a patient is checked and T cells are collected. Then, these T cells are made to find cancer cells. After that, the patient gets chemotherapy to prepare. Lastly, the modified T cells are given back to the patient.

What are the possible side effects of CAR T cell therapy?

Side effects can include a reaction from the body, brain problems, and other issues. But, doctors have ways to manage these problems.

How successful is CAR T cell therapy for lymphoma?

It has shown great promise in treating lymphoma. The success rate varies based on the type of lymphoma and the patient’s health.

What is the cost of CAR T cell therapy?

The treatment is expensive. But, there are ways to help with the cost. Insurance and financial help programs are available.

Is CAR T cell therapy FDA-approved for lymphoma?

Yes, some CAR T cell products are approved by the FDA for lymphoma. Rules in other countries may be different.

What is the future of CAR T cell therapy in lymphoma care?

The future looks bright. New versions of CAR T cell therapy are being developed. They aim to overcome treatment resistance and help more patients.

How do I access CAR T cell therapy?

To get this therapy, talk to your doctor. Find a qualified center and look into insurance and financial help.

What are the benefits of CAR T cell therapy compared to traditional lymphoma treatments?

It offers a chance for a cure for patients with hard-to-treat lymphoma. It’s more focused and precise than traditional treatments.

i

Medical Disclaimer

The content on this page is for informational purposes only and is not a substitute for professional medical advice, diagnosis or treatment. Always consult a qualified healthcare provider regarding any medical conditions.

Get a Free Quote

Response within 2 hours during business hours

Clinics/branches
GDPR

Related Doctors

Assoc. Prof. MD. Evrim Duman Liv Hospital Ulus Assoc. Prof. MD. Evrim Duman Radiation Oncology Asst. Prof. MD. Meltem Topalgökçeli Selam Liv Hospital Ulus Asst. Prof. MD. Meltem Topalgökçeli Selam Medical Oncology Prof. MD. Duygu Derin Liv Hospital Ulus Prof. MD. Duygu Derin Medical Oncology Prof. MD. Emre Merdan Fayda Liv Hospital Ulus Prof. MD. Emre Merdan Fayda Radiation Oncology Prof. MD. Meral Günaldı Liv Hospital Ulus Prof. MD. Meral Günaldı Medical Oncology Assoc. Prof. MD. Murat Ayhan Liv Hospital Vadistanbul Assoc. Prof. MD. Murat Ayhan Medical Oncology Prof. MD.  Itır Şirinoğlu Demiriz Liv Hospital Vadistanbul Prof. MD. Itır Şirinoğlu Demiriz Hematology Prof. MD. Tülin Tıraje Celkan Liv Hospital Vadistanbul Prof. MD. Tülin Tıraje Celkan Pediatric Hematology and Oncology Assoc. Prof. MD. Erkan Kayıkçıoğlu Liv Hospital Bahçeşehir Assoc. Prof. MD. Erkan Kayıkçıoğlu Medical Oncology Assoc. Prof. MD. Mine Dağgez Liv Hospital Bahçeşehir Assoc. Prof. MD. Mine Dağgez Gynecological Oncology Assoc. Prof. MD. Ozan Balakan Liv Hospital Bahçeşehir Assoc. Prof. MD. Ozan Balakan Medical Oncology MD. Taylan Bükülmez Liv Hospital Bahçeşehir MD. Taylan Bükülmez Radiation Oncology Op. MD. Alp Koray Kinter Liv Hospital Bahçeşehir Op. MD. Alp Koray Kinter Gynecological Oncology Prof. MD. Nuri Faruk Aykan Liv Hospital Bahçeşehir Prof. MD. Nuri Faruk Aykan Medical Oncology Prof. MD. Yasemin Altuner Torun Liv Hospital Bahçeşehir Prof. MD. Yasemin Altuner Torun Pediatric Hematology and Oncology Spec. MD. Özlem Doğan Liv Hospital Bahçeşehir Spec. MD. Özlem Doğan Medical Oncology Assoc. Prof. MD. Emir Çelik Liv Hospital Topkapı Assoc. Prof. MD. Emir Çelik Medical Oncology Assoc. Prof. MD. Muhammed Mustafa Atcı Liv Hospital Topkapı Assoc. Prof. MD. Muhammed Mustafa Atcı Medical Oncology Prof. MD. İrfan Çiçin Liv Hospital Topkapı Prof. MD. İrfan Çiçin Medical Oncology Assoc. Prof. MD.  Ramazan Öcal Liv Hospital Ankara Assoc. Prof. MD. Ramazan Öcal Hematology Assoc. Prof. MD. Nazlı Topfedaisi Özkan Liv Hospital Ankara Assoc. Prof. MD. Nazlı Topfedaisi Özkan Gynecological Oncology Prof. MD. Fikret Arpacı Liv Hospital Ankara Prof. MD. Fikret Arpacı Medical Oncology Prof. MD. Gökhan Erdem Liv Hospital Ankara Prof. MD. Gökhan Erdem Medical Oncology Prof. MD. Meral Beksaç Liv Hospital Ankara Prof. MD. Meral Beksaç Hematology Prof. MD. Oral Nevruz Liv Hospital Ankara Prof. MD. Oral Nevruz Hematology Prof. MD. Saadettin Kılıçkap Liv Hospital Ankara Prof. MD. Saadettin Kılıçkap Medical Oncology Prof. MD. Sadık Muallaoğlu Liv Hospital Ankara Prof. MD. Sadık Muallaoğlu Medical Oncology Spec. MD. Ender Kalacı Liv Hospital Ankara Spec. MD. Ender Kalacı Medical Oncology Assoc. Prof. MD. Fadime Ersoy Dursun Liv Hospital Gaziantep Assoc. Prof. MD. Fadime Ersoy Dursun Hematology Prof. MD. Fatih Teker Liv Hospital Gaziantep Prof. MD. Fatih Teker Medical Oncology Spec. MD. ELXAN MEMMEDOV Liv Bona Dea Hospital Bakü Spec. MD. ELXAN MEMMEDOV Medical Oncology Spec. MD. Ceyda Aslan Spec. MD. Ceyda Aslan Hematology Spec. MD. Elkhan Mammadov Spec. MD. Elkhan Mammadov Medical Oncology Spec. MD. Elmir İsrafilov Spec. MD. Elmir İsrafilov Hematology Spec. MD. Minure Abışova Eliyeva Spec. MD. Minure Abışova Eliyeva Hematology Spec. MD. Natavan Azizova Spec. MD. Natavan Azizova Medical Oncology Prof. MD. Mehmet Hilmi Doğu Liv Hospital Ulus + Liv Hospital Bahçeşehir Prof. MD. Mehmet Hilmi Doğu Hematology
Trusted Worldwide
30
Years of
Experience
30 Years Badge
Health Türkiye Accreditation

Trusted Worldwide

30 Years of Experience

Patient Reviews
Reviews from 9,651
4,9
Was this content helpful?
Your feedback helps us improve.
What did you like?
Share more details about your experience.
You must give consent to continue.

Thank you!

Your feedback has been submitted successfully. Your input is valuable in helping us improve.

Book a Free Certified Online
Doctor Consultation

Clinics/branches
GDPR

We're Here to Help.
Get in Touch

Send us all your questions or requests, and our
expert team will assist you.

Our Doctors

Assoc. Prof. MD. Evrim Duman Radiation Oncology

Assoc. Prof. MD. Evrim Duman

Liv Hospital Ulus
Asst. Prof. MD. Meltem Topalgökçeli Selam Medical Oncology

Asst. Prof. MD. Meltem Topalgökçeli Selam

Liv Hospital Ulus
Prof. MD. Duygu Derin Medical Oncology

Prof. MD. Duygu Derin

Liv Hospital Ulus
Prof. MD. Emre Merdan Fayda Radiation Oncology

Prof. MD. Emre Merdan Fayda

Liv Hospital Ulus
Prof. MD. Mehmet Hilmi Doğu Hematology

Prof. MD. Mehmet Hilmi Doğu

Liv Hospital Ulus
Liv Hospital Bahçeşehir
Prof. MD. Meral Günaldı Medical Oncology

Prof. MD. Meral Günaldı

Liv Hospital Ulus
Assoc. Prof. MD. Murat Ayhan Medical Oncology

Assoc. Prof. MD. Murat Ayhan

Liv Hospital Vadistanbul
Prof. MD.  Itır Şirinoğlu Demiriz Hematology

Prof. MD. Itır Şirinoğlu Demiriz

Liv Hospital Vadistanbul
Prof. MD. Tülin Tıraje Celkan Pediatric Hematology and Oncology

Prof. MD. Tülin Tıraje Celkan

Liv Hospital Vadistanbul
Assoc. Prof. MD. Erkan Kayıkçıoğlu Medical Oncology

Assoc. Prof. MD. Erkan Kayıkçıoğlu

Liv Hospital Bahçeşehir
Assoc. Prof. MD. Mine Dağgez Gynecological Oncology

Assoc. Prof. MD. Mine Dağgez

Liv Hospital Bahçeşehir
Assoc. Prof. MD. Ozan Balakan Medical Oncology

Assoc. Prof. MD. Ozan Balakan

Liv Hospital Bahçeşehir
MD. Taylan Bükülmez Radiation Oncology

MD. Taylan Bükülmez

Liv Hospital Bahçeşehir
Op. MD. Alp Koray Kinter Gynecological Oncology

Op. MD. Alp Koray Kinter

Liv Hospital Bahçeşehir
Prof. MD. Nuri Faruk Aykan Medical Oncology

Prof. MD. Nuri Faruk Aykan

Liv Hospital Bahçeşehir
Prof. MD. Yasemin Altuner Torun Pediatric Hematology and Oncology

Prof. MD. Yasemin Altuner Torun

Liv Hospital Bahçeşehir
Spec. MD. Özlem Doğan Medical Oncology

Spec. MD. Özlem Doğan

Liv Hospital Bahçeşehir
Assoc. Prof. MD. Emir Çelik Medical Oncology

Assoc. Prof. MD. Emir Çelik

Liv Hospital Topkapı
Assoc. Prof. MD. Muhammed Mustafa Atcı Medical Oncology

Assoc. Prof. MD. Muhammed Mustafa Atcı

Liv Hospital Topkapı
Prof. MD. İrfan Çiçin Medical Oncology

Prof. MD. İrfan Çiçin

Liv Hospital Topkapı
Assoc. Prof. MD.  Ramazan Öcal Hematology

Assoc. Prof. MD. Ramazan Öcal

Liv Hospital Ankara
Assoc. Prof. MD. Nazlı Topfedaisi Özkan Gynecological Oncology

Assoc. Prof. MD. Nazlı Topfedaisi Özkan

Liv Hospital Ankara
Prof. MD. Fikret Arpacı Medical Oncology

Prof. MD. Fikret Arpacı

Liv Hospital Ankara
Prof. MD. Gökhan Erdem Medical Oncology

Prof. MD. Gökhan Erdem

Liv Hospital Ankara
Prof. MD. Meral Beksaç Hematology

Prof. MD. Meral Beksaç

Liv Hospital Ankara
Prof. MD. Oral Nevruz Hematology

Prof. MD. Oral Nevruz

Liv Hospital Ankara
Prof. MD. Saadettin Kılıçkap Medical Oncology

Prof. MD. Saadettin Kılıçkap

Liv Hospital Ankara
Prof. MD. Sadık Muallaoğlu Medical Oncology

Prof. MD. Sadık Muallaoğlu

Liv Hospital Ankara
Spec. MD. Ender Kalacı Medical Oncology

Spec. MD. Ender Kalacı

Liv Hospital Ankara
Assoc. Prof. MD. Fadime Ersoy Dursun Hematology

Assoc. Prof. MD. Fadime Ersoy Dursun

Liv Hospital Gaziantep
Prof. MD. Fatih Teker Medical Oncology

Prof. MD. Fatih Teker

Liv Hospital Gaziantep
Spec. MD. ELXAN MEMMEDOV Medical Oncology

Spec. MD. ELXAN MEMMEDOV

Liv Bona Dea Hospital Bakü
Spec. MD. Ceyda Aslan Hematology

Spec. MD. Ceyda Aslan

Spec. MD. Elkhan Mammadov Medical Oncology

Spec. MD. Elkhan Mammadov

Spec. MD. Elmir İsrafilov Hematology

Spec. MD. Elmir İsrafilov

Spec. MD. Minure Abışova Eliyeva Hematology

Spec. MD. Minure Abışova Eliyeva

Spec. MD. Natavan Azizova Medical Oncology

Spec. MD. Natavan Azizova

Need Help? Chat with our medical team

Let's Talk on WhatsApp

📌

Get instant answers from our medical team. No forms, no waiting — just tap below to start chatting now.

or call us at +90 530 174 42 01